Marie-Louise Hyre Arpe1,2, Sascha Rørvig1,2, Karin Kok1, Christian Mølgaard1,2, Thomas Leth Frandsen3. 1. Pediatric Nutrition Unit, Copenhagen University Hospital, Rigshospitalet, Denmark. 2. Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. 3. Department of Child and Youth, Copenhagen University Hospital, Rigshospitalet, Denmark. thomas.leth.frandsen@regionh.dk.
Abstract
PURPOSE: Few studies have addressed the common issue of weight gain in children with acute lymphoblastic leukemia (ALL) during early phases of treatment, and even fewer have used the appropriate measure for weight fluctuation in children, BMI-for-age z-scores (BAZs). The purpose of this study is thus to measure the extent of the weight gain in BAZ during the 150 first days of treatment and to identify factors associated with the weight gain. Furthermore, we wish to raise the question of whether changes in treatment protocols automatically should be followed by an evaluation of the nutritional guidelines. METHOD: In this retrospective study, the medical records of 51 children with ALL treated with the NOPHO ALL 2008 protocol at Copenhagen University Hospital were assessed. Patient characteristics were extracted, and height, weight, and age during the first 150 days of treatment were converted to BAZ. RESULTS: During 150 days of treatment, the proportion of overweight/obese patients increased significantly from 9.8 to 33.3 %. The mean change in BAZ (∆BAZ) was +1 standard deviation (0.02 ± 1.16 vs. 1.12 ± 1.44; p < 0.001) and BAZ increased significantly during periods with glucocorticoid (GC) treatment but not in periods without GC. ΔBAZ was larger in boys compared to girls, and ΔBAZ was higher in patients who were under/normal weight at diagnosis, compared to patients who were overweight/obese (1.26 ± 1.29 vs. -0.04 ± 0.41; p = 0.032). CONCLUSION: BAZ increased significantly in children with ALL during the initial treatment with the NOPHO ALL 2008 protocol. This is likely associated with the GC administration and influenced by gender and initial BAZ.
PURPOSE: Few studies have addressed the common issue of weight gain in children with acute lymphoblastic leukemia (ALL) during early phases of treatment, and even fewer have used the appropriate measure for weight fluctuation in children, BMI-for-age z-scores (BAZs). The purpose of this study is thus to measure the extent of the weight gain in BAZ during the 150 first days of treatment and to identify factors associated with the weight gain. Furthermore, we wish to raise the question of whether changes in treatment protocols automatically should be followed by an evaluation of the nutritional guidelines. METHOD: In this retrospective study, the medical records of 51 children with ALL treated with the NOPHO ALL 2008 protocol at Copenhagen University Hospital were assessed. Patient characteristics were extracted, and height, weight, and age during the first 150 days of treatment were converted to BAZ. RESULTS: During 150 days of treatment, the proportion of overweight/obesepatients increased significantly from 9.8 to 33.3 %. The mean change in BAZ (∆BAZ) was +1 standard deviation (0.02 ± 1.16 vs. 1.12 ± 1.44; p < 0.001) and BAZ increased significantly during periods with glucocorticoid (GC) treatment but not in periods without GC. ΔBAZ was larger in boys compared to girls, and ΔBAZ was higher in patients who were under/normal weight at diagnosis, compared to patients who were overweight/obese (1.26 ± 1.29 vs. -0.04 ± 0.41; p = 0.032). CONCLUSION:BAZ increased significantly in children with ALL during the initial treatment with the NOPHO ALL 2008 protocol. This is likely associated with the GC administration and influenced by gender and initial BAZ.
Authors: Jitesh D Kawedia; Sue C Kaste; Deqing Pei; John C Panetta; Xiangjun Cai; Cheng Cheng; Geoffrey Neale; Scott C Howard; William E Evans; Ching-Hon Pui; Mary V Relling Journal: Blood Date: 2010-12-10 Impact factor: 22.113
Authors: Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: B Bernbeck; A Christaras; K Krauth; S Lentrodt; H Strelow; J Schaper; G Janssen; U Mödder; U Göbel Journal: Klin Padiatr Date: 2004 Nov-Dec Impact factor: 1.349
Authors: Virginia Kimball Dalton; Montse Rue; Lewis B Silverman; Richard D Gelber; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall Schorin; Nancy J Tarbell; Stephen E Sallan; Laurie E Cohen Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: Laura B Ramsey; Stan Pounds; Cheng Cheng; Xueyuan Cao; Wenjian Yang; Colton Smith; Seth E Karol; Chengcheng Liu; John C Panetta; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Raul C Ribeiro; John T Sandlund; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Pharmacogenet Genomics Date: 2017-08 Impact factor: 2.089
Authors: Martin Kaj Fridh; Casper Simonsen; Peter Schmidt-Andersen; Anne Anker Nissen; Jesper Frank Christensen; Anders Larsen; Abigail L Mackey; Hanne Bækgaard Larsen; Klaus Müller Journal: Bone Marrow Transplant Date: 2021-06-21 Impact factor: 5.483
Authors: Anna Pouplier; Hanne Baekgaard Larsen; Jan Christensen; Peter Schmidt-Andersen; Helle Winther; Martin Kaj Fridh Journal: Front Pediatr Date: 2022-09-27 Impact factor: 3.569
Authors: Troels Thorsteinsson; Hanne Baekgaard Larsen; Kjeld Schmiegelow; Lone Friis Thing; Peter Krustrup; Mogens Theisen Pedersen; Karl Bang Christensen; Pernille Rudebeck Mogensen; Anne Sofie Helms; Lars Bo Andersen Journal: BMJ Open Sport Exerc Med Date: 2017-05-12